Barclays downgrades Polypeptide after strong H1 rally, Samsung offer

Barclays has reduced its rating of Polypeptide Group AG to "equal weight" from "overweight," recognizing the stock's impressive first-half performance. The company delivered strong results, surpassing expectations with a high-single-digit percentage sales and earnings before interest, taxes, depreciation, and amortization (EBITDA) increase.

Barclays has raised its price target to 44.31 Swiss francs per share, matching Samsung Biologics' all-cash offer to acquire Polypeptide shares. Polypeptide has surged 68.8% year-to-date, while the STOXX Europe 600 Health Care index has declined by 0.5%. Samsung Biologics, a South Korean biotech company, recently unveiled its all-cash offer for Polypeptide on July 20 at 44.31 francs per share, a 40% premium.

The offer is bolstered by Draupnir Holding, the majority shareholder of Polypeptide, committing to tender its stake and gaining unanimous approval from the company's board and independent fairness committee. Barclays has also revised its sales and EBITDA forecasts for the next three years, reflecting the company's impressive performance and higher general and administrative expenses.

However, risks to Barclays' price target include the success of the Samsung offer, potential capacity expansion delays or accelerations, and contract cancellations or announcements.